Clinical Trials
28
Active:1
Completed:21
Trial Phases
3 Phases
Phase 1:4
Phase 2:11
Phase 3:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 2
11 (44.0%)Phase 3
10 (40.0%)Phase 1
4 (16.0%)A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
Phase 1
Completed
- Conditions
- Healthy Study Participants
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06679413
- Locations
- 🇺🇸
Up0132 1001, Baltimore, Maryland, United States
Doxecitine and Doxribtimine-Expanded Access
- Conditions
- Thymine Kinase 2 Deficiency
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Registration Number
- NCT06590493
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06118255
- Locations
- 🇺🇸
Ep0213 106, Orange, California, United States
🇺🇸Ep0213 102, Winston-Salem, North Carolina, United States
🇺🇸Ep0213 105, Memphis, Tennessee, United States
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
Phase 2
Active, not recruiting
- Conditions
- Thymidine Kinase 2 Deficiency
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03845712
- Locations
- 🇺🇸
Tk0102 1005, New York, New York, United States
🇮🇱Tk0102 4038, Haifa, Israel
🇮🇱Tk0102 4039, Holon, Israel
Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02806219
- Locations
- 🇺🇸
Ra0132 001, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found